Fundraising Fox
Borealis Biosciences
Founded 2024 · 57 employees on LinkedIn · 2 known investors
Find your way into Borealis Biosciences
Sign up to see every warm intro you have to Borealis Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Borealis Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.
Investors · 2
Westlake Village BioPartnerslisted by Westlake Village BioPartnersLos Angeles · $100K – $5M
How we know: Westlake Village BioPartners's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Versant VenturesreportedSan Francisco · $250K – $5M
How we know: a partner's Signal profile · Not right? Tell us
Related companies · 4
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Chrysalis BiotherapeuticsChrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies working in the same space as Borealis Biosciences.
Frequently asked questions
- What does Borealis Biosciences do?
- Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.
- Who are Borealis Biosciences's investors?
- Borealis Biosciences's investors include Westlake Village BioPartners, Versant Ventures.